Herren Wu is Chief Technology Officer and Global Head of Antibody Discovery and Protein Engineering (ADPE) at MedImmune. Herren founded the Department of Antibody Discovery and Protein Engineering in January 2002, when he joined MedImmune as Director. He was promoted to Senior Director in 2004 and Vice-President in 2006. He was also the founding department head for Biosuperiors R&D and led this organisation for three years (2010-2013). During his tenure, Herren has successfully integrated ADPE platforms across all sites following the MedImmune/Cambridge Antibody Technology (CAT) merger. Under his leadership, ADPE developed many proprietary cutting-edge technology platforms, including half-life extension technology (YTE), bi-specifics/multi-specifics, protein scaffolds, antibody-drug conjugates, Blood-Brain-Barrier technology, peptide therapeutics, phenotypic screening and most recently mass-spec proteomics and non-natural amino acid technology. In 2006, Herren received the Senior Technology Fellow Emerald Honors award. He is also an inventor on 43 granted patents and 50 patent applications related to antibody/protein therapeutics and technologies. This is in addition to more than 60 manuscript publications. Herren received his bachelor’s degree in Chemistry from the National Taiwan University and his doctorate in Molecular and Cellular Biology from the University of Massachusetts, Amherst. He completed his postdoctoral training at The Scripps Research Institute in La Jolla, California.